<DOC>
	<DOCNO>NCT01752569</DOCNO>
	<brief_summary>Cancer lead cause death individual live human immunodeficiency virus ( HIV ) , Kaposi 's sarcoma ( KS ) remain common HIV-associated cancer . KS cause individual become infected HIV another virus , Human herpesvirus-8 ( HHV-8 ) . Laboratory study show HHV-8 stimulate biological pathway within KS lesion promote growth . Selumetinib target pathways may therefore useful new therapy KS . Phase I trial aim identify best dose use selumetinib investigate effect selumetinib treatment anti-viral treatment HIV patient receive control HIV infection . Phase II trial investigate well selumetinib work treatment KS best dose determine phase I .</brief_summary>
	<brief_title>A Study Selumetinib Patients With Kaposi 's Sarcoma</brief_title>
	<detailed_description>BACKGROUND AND RATIONALE HIV AND KS The prevalence HIV United Kingdom ( UK ) rise 83,000 living HIV 7,000 new case per annum ( pa ) . At diagnosis third patient severe immune-suppression cluster differentiation 4 ( CD4 ) positive cell count le 200/mm3 ( HPA , 2009 ) , associate opportunistic infection increase various tumour . Cancer lead cause death individual live HIV , KS remain common AIDS-associated malignancy . In UK prospective cohort follow Highly Active Anti-Retroviral Therapy ( HAART ) era , 5.5 % HIV positive patient develop KS ( Stebbing et al. , 2006 ) . KS associate co-infection HIV human herpesvirus-8 ( HHV-8 ) . Patients typically present multi-focal cutaneous disease often associate lymphoedema . Extra-cutaneous disease commonly involve gastrointestinal tract , lung , liver spleen . For early KS , initiation HAART may sufficient control disease radiotherapy benefit localise disease ( Di Lorenzo et al. , 2007 ) . Currently alternative progressive localise disease cytotoxic chemotherapy . Cytotoxic chemotherapy liposomal anthracycline taxanes , indicate patient widespread cutaneous KS , extensive oral disease symptomatic visceral involvement ( Bower et al. , 2008 ) . Pegylated liposomal doxorubicin ( PLD ) 20mg/m2 q 3 week first-line therapy combination HAART report give tumour response 55 % patient median progression free survival ( PFS ) 22 week ( Cooley et al. , 2007 ) . Second-line therapy low dose paclitaxel ( 100mg/m2 q 2 week ) report give response rate 56 % median PFS 39 week ( Tulpule et al. , 2002 ) . However majority patient ' progress despite chemotherapy new treatment alternative require . JUSTIFICATION FOR DESIGN Selumetinib test number phase I phase II trial monotherapy combine cytotoxic chemotherapy patient advance solid malignancy . A toxicity profile recommend dose establish patient . Selumetinib test combination HAART . No significant interaction predict Selumetinib HAART however phase I study required investigate pharmacokinetic effect combine drug . In particular wish establish Selumetinib reduce efficacy HAART . This trial open-label multi-centre phase I/II study investigate use selumetinib potential treatment HIV-associated KS . Phase I accelerate dose finding study dose commence 1 dose level recommend monotherapy combination cytotoxic chemotherapy . The aims phase I identify maximum tolerate dose ( MTD ) selumetinib patient HAART whilst prove selumetinib reduce efficacy HAART . Phase II aim provide evidence efficacy selumetinib treatment KS . Evidence efficacy assess via objective response rate treatment use develop protocol future randomise phase II/III study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<criteria>Histologically confirm KS . Measurable disease accord ACTG criterion . Evidence disease progression past 6 month . No anticancer treatment within one month prior commence trial treatment . Progressive cutaneous nodal KS require chemotherapy OR progressive KS follow cytotoxic chemotherapy . Adequate haematological function : Haemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1.5 x 10 9/L Platelets ≥ 100 x 10 9/L Adequate hepatic function : Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) , except patient establish antiretroviral drug atazanavir ( upper limit ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level ≤ 2.5 x ULN ALT ≤ 2.5 x ULN AST ≤ 2.5 x ULN Adequate renal function : Serum creatinine clearance &gt; 50 ml/min ( CockcroftGault formula 24 hour urine collection ) . Left ventricular function &gt; 50 % normal Age ≥ 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . For selumetinib , woman child bear age child bear potential MUST negative pregnancy test prior study entry AND use adequate contraception method , must continue treatment least 4 week study treatment end . Male patient must agree use effective contraception method treatment least 16 week study treatment end ( barrier contraception recommend individual live HIV ) . Written inform consent HIV viral load &gt; 200 copies/ml . Any previous treatment Ras , Raf MEK inhibitor . Active opportunistic infection . Known hepatitis B , hepatitis C. Clinical evidence uncontrolled hypertension ( systolic BP &gt; 150 mmHg diastolic BP &gt; 90 mmHg 2 reading ≥ 1 hour apart ) . Clinical evidence heart failure ( New York Heart Association ≥Class II ) . Clinical evidence atrial fibrillation ( heart rate &gt; 100 bpm ) unstable ischaemic heart disease ( MI within 6 month prior start treatment angina require use nitrate &gt; weekly ) . Major surgery within 4 week prior start selumetinib . Evidence psychological , familial , sociological geographical condition potentially hamper protocol compliance . Clinical judgement Investigator patient participate study . Refractory nausea , vomit , chronic gastrointestinal disease ( e.g . inflammatory bowel disease ) significant bowel resection would preclude adequate absorption . Treatment investigational product within 28 day registration Pregnant breastfeeding woman . Japanese ethnicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Kaposi 's sarcoma</keyword>
	<keyword>Anti-retroviral therapy</keyword>
	<keyword>HAART</keyword>
	<keyword>AIDS</keyword>
</DOC>